PET-CT Diagnostic and Evaluation Role in Patients with Nodal Lymphoma

Abstract

Background: The most prevalent hematological malignancy, malignant lymphoma, makes up around 8% of all adult malignancies. Non-Hodgkin lymphoma (NHL) and Hodgkin disorder (HD) are two types of lymphoid neoplasms. Aim of the Work: Examine how PET/CT may be used to diagnose nodal lymphoma. Analyze the effectiveness of (18 FDG PET/CT) in the first staging of nodal lymphoma. Analyze the function of PET-CT in patient monitoring both during and after the therapeutic course. Examine the function of PET-CT in foretelling and spotting relapses. Patients and Methods: Thirty patients (12 female and 18 males; 11 HD, 19 NHD) with histologically confirmed malignant lymphoma were enrolled in this investigation. They were split into three groups judging by the outcomes of the PET/CT examination. Results: CT for diagnosis was compared to PET/CT results. The current study demonstrated the critical relevance of PET/CT in lymphoma staging, monitoring therapeutic response, and follow-up. The present investigation demonstrated the significance of 18F-FDG. When it comes to the early staging of lymphomas, PET/CT has shown to be a valuable tool in the treatment of lymphomas. PET/CT exhibited substantial effects on early and delayed therapy response evaluation. Conclusion: The outcomes of the present research highlighted the value of 18F- FDG PET/CT as a technique for the first staging of lymphomas. Comparing PET/CT to diagnostic CT has major consequences for early and delayed evaluation of therapy response.